Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp,Michael Kuligowski,Eric Simpson,Jacek Szepietowski,May Venturanza,Leon Kircik,Seth Forman,Kang Sun,Darryl Toth,Lawrence Eichenfeld

doi:10.25251/skin.5.supp.63

Abstract

N/A

Highlights

Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies
● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of JAK1 and JAK24
EASI-75, ≥75% improvement from baseline in Eczema Area and Severity Index score; IGA-TS, Investigator’s Global Assessment-treatment success; NRS4, ≥4-point improvement in itch numerical rating scale score from baseline; PROMIS, Patient-Reported Outcomes Measurement Information System; RUX, ruxolitinib cream

Summary

Introduction

● The pathogenesis of AD involves Janus kinases (JAKs) acting downstream of proinflammatory cytokines and itch mediators. ● Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of JAK1 and JAK24. ● In two phase 3 randomized studies of identical design (TRuE-AD1 [NCT03745638] and TRuE-AD2 [NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD4 (Figure 1). EASI-75, ≥75% improvement from baseline in Eczema Area and Severity Index score; IGA-TS, Investigator’s Global Assessment-treatment success; NRS4, ≥4-point improvement in itch numerical rating scale score from baseline; PROMIS, Patient-Reported Outcomes Measurement Information System; RUX, ruxolitinib cream. ** P

Study Design and Patients

Results

Conclusions

Disclosures